Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (17773)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 21, 2017 (publication date) through Dec 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(15): 2771-2784 [PMID: 28487615 DOI: 10.3748/wjg.v23.i15.2771] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i15/2771.htm |
| Number | Citing Articles |
| 1 |
Kara Wegermann, Catherine Howe, Ricardo Henao, Ying Wang, Cynthia D. Guy, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan. Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver‐Related Events in Nonalcoholic Fatty Liver Disease. Hepatology Communications 2021; 5(4): 608 doi: 10.1002/hep4.1665
|
| 2 |
Xuechun Liu, Lei Han, Shenghua Bi, Xueli Ding, Qi Sheng, Yueping Jiang, Ge Guan, Qinghui Niu, Xue Jing. Differential metabolites in cirrhotic patients with hepatitis B and muscle mass loss. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1068779
|
| 3 |
Rui Su, Hui-Ling Fu, Qian-Xue Zhang, Chen-Yan Wu, Guan-Yu Yang, Jun-Jie Wu, Wen-Jie Cao, Jin Liu, Zhong-Ping Jiang, Cong-Jun Xu, Yong Rao, Ling Huang. Amplifying hepatic L-aspartate levels suppresses CCl4-induced liver fibrosis by reversing glucocorticoid receptor β-mediated mitochondrial malfunction. Pharmacological Research 2024; 206: 107294 doi: 10.1016/j.phrs.2024.107294
|
| 4 |
Lucia Carulli, Giulia Zanca, Filippo Schepis, Erica Villa. RETRACTED: The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites 2019; 9(2): 25 doi: 10.3390/metabo9020025
|
| 5 |
Ying Zhu, Qingce Zang, Zhigang Luo, Jiuming He, Ruiping Zhang, Zeper Abliz. An Organ-Specific Metabolite Annotation Approach for Ambient Mass Spectrometry Imaging Reveals Spatial Metabolic Alterations of a Whole Mouse Body. Analytical Chemistry 2022; 94(20): 7286 doi: 10.1021/acs.analchem.2c00557
|
| 6 |
Dragana Savic, Leanne Hodson, Stefan Neubauer, Michael Pavlides. The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020; 12(8): 2178 doi: 10.3390/nu12082178
|
| 7 |
Tao Tang, Ya Li, Jie Wang, Mauricio A. Elzo, Jiahao Shao, Yanhong Li, Siqi Xia, Huimei Fan, Xianbo Jia, Songjia Lai. Untargeted Metabolomics Reveals Intestinal Pathogenesis and Self-Repair in Rabbits Fed an Antibiotic-Free Diet. Animals 2021; 11(6): 1560 doi: 10.3390/ani11061560
|
| 8 |
Xuemei Wang, Benchen Rao, Haiyu Wang, Chao Liu, Zhigang Ren, Zujiang Yu. Serum metabolome alterations in patients with early nonalcoholic fatty liver disease. Bioscience Reports 2022; 42(10) doi: 10.1042/BSR20220319
|
| 9 |
Abraham Joseph Pellissery, Poonam Gopika Vinayamohan, Leya Susan Viju, Divya Joseph, Kumar Venkitanarayanan. Advances and Challenges in Urine Laboratory Analysis. 2024; doi: 10.5772/intechopen.109808
|
| 10 |
Runbin Sun, Haokai Zhao, Shuzhen Huang, Ran Zhang, Zhenyao Lu, Sijia Li, Guangji Wang, Jiye Aa, Yuan Xie. Prediction of Liver Weight Recovery by an Integrated Metabolomics and Machine Learning Approach After 2/3 Partial Hepatectomy. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.760474
|
| 11 |
Xuehua Yan, Hongbing Liu, Meng Huang, Yujie Zhang, Binfang Zeng. Integrative proteomics and metabolomics explore the effect and mechanism of Qiyin granules on improving nonalcoholic fatty liver disease. Heliyon 2024; 10(5): e27075 doi: 10.1016/j.heliyon.2024.e27075
|
| 12 |
Application of Metabolomics in Diagnosis and Treatment of Chronic Liver Diseases. Critical Reviews in Analytical Chemistry 2022; 52(5): 906 doi: 10.1080/10408347.2020.1842172
|
| 13 |
George V. Dedoussis, Athina I. Amanatidou. NAFLD and NASH. 2020; : 181 doi: 10.1007/978-3-030-37173-9_10
|
| 14 |
Lili Niu, Karolina Sulek, Catherine G. Vasilopoulou, Alberto Santos, Nicolai J. Wewer Albrechtsen, Simon Rasmussen, Florian Meier, Matthias Mann. Defining NASH from a Multi-Omics Systems Biology Perspective. Journal of Clinical Medicine 2021; 10(20): 4673 doi: 10.3390/jcm10204673
|
| 15 |
Anastasiia Driuchina, Jukka Hintikka, Marko Lehtonen, Pekka Keski-Rahkonen, Thomas O’Connell, Risto Juvonen, Juho Kuula, Antti Hakkarainen, Jari A. Laukkanen, Elina Mäkinen, Sanna Lensu, Kirsi H. Pietiläinen, Satu Pekkala, Elizabeth K. Mallott, Avery August. Identification of Gut Microbial Lysine and Histidine Degradation and CYP-Dependent Metabolites as Biomarkers of Fatty Liver Disease. mBio 2023; 14(1) doi: 10.1128/mbio.02663-22
|
| 16 |
Ji-Hee Haam, Yun Kyong Lee, Eunkyung Suh, Young-Sang Kim. Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. Diagnostics 2022; 12(5): 1199 doi: 10.3390/diagnostics12051199
|
| 17 |
Mingzhe Zhu, Meng Li, Wenjun Zhou, Guangbo Ge, Li Zhang, Guang Ji. Metabolomic Analysis Identifies Glycometabolism Pathways as Potential Targets of Qianggan Extract in Hyperglycemia Rats. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00671
|
| 18 |
Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle. Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences 2024; 25(23): 12809 doi: 10.3390/ijms252312809
|
| 19 |
Xiangnan Ren, Wu Fan, Zixing Shao, Kaiyun Chen, Xuefeng Yu, Qionglin Liang. A metabolomic study on early detection of steroid-induced avascular necrosis of the femoral head. Oncotarget 2018; 9(8): 7984 doi: 10.18632/oncotarget.24150
|
| 20 |
Isabelle Alldritt, Paul L. Greenhaff, Daniel J. Wilkinson. Metabolomics as an Important Tool for Determining the Mechanisms of Human Skeletal Muscle Deconditioning. International Journal of Molecular Sciences 2021; 22(24): 13575 doi: 10.3390/ijms222413575
|
| 21 |
Ambrin Farizah Babu, Susanne Csader, Ville Männistö, Milla-Maria Tauriainen, Heikki Pentikäinen, Kai Savonen, Anton Klåvus, Ville Koistinen, Kati Hanhineva, Ursula Schwab. Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-10481-9
|
| 22 |
Da Jung Kim, Seonghae Yoon, Sang Chun Ji, Jinho Yang, Yoon-Keun Kim, SeungHwan Lee, Kyung-Sang Yu, In-Jin Jang, Jae-Yong Chung, Joo-Youn Cho. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-30349-1
|
| 23 |
Qiang Yang, Ai-hua Zhang, Jian-hua Miao, Hui Sun, Ying Han, Guang-li Yan, Fang-fang Wu, Xi-jun Wang. Metabolomics biotechnology, applications, and future trends: a systematic review. RSC Advances 2019; 9(64): 37245 doi: 10.1039/C9RA06697G
|
| 24 |
Sihyang Jo, Jin-Mo Kim, Minshu Li, Han Sun Kim, Yong Jin An, Sunghyouk Park. TAT as a new marker and its use for noninvasive chemical biopsy in NASH diagnosis. Molecular Medicine 2024; 30(1) doi: 10.1186/s10020-024-00992-8
|
| 25 |
Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World Journal of Hepatology 2021; 13(11): 1494-1511 doi: 10.4254/wjh.v13.i11.1494
|
| 26 |
Mingmei Shao, Yifei Lu, Hongjiao Xiang, Junmin Wang, Guang Ji, Tao Wu. Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.971561
|
| 27 |
Maria Del Ben, Diletta Overi, Licia Polimeni, Guido Carpino, Giancarlo Labbadia, Francesco Baratta, Daniele Pastori, Valeria Noce, Eugenio Gaudio, Francesco Angelico, Carmine Mancone. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. International Journal of Molecular Sciences 2018; 19(2): 603 doi: 10.3390/ijms19020603
|
| 28 |
Elisa Gurian, Pablo Giraudi, Natalia Rosso, Claudio Tiribelli, Deborah Bonazza, Fabrizio Zanconati, Michela Giuricin, Silvia Palmisano, Nicolò de Manzini, Valter Sergo, Alois Bonifacio. Differentiation between stages of non-alcoholic fatty liver diseases using surface-enhanced Raman spectroscopy. Analytica Chimica Acta 2020; 1110: 190 doi: 10.1016/j.aca.2020.02.040
|
| 29 |
Zohre Mozduri, Nathalie Marty-Gasset, Bara Lo, Ali Akbar Masoudi, Mireille Morisson, Cécile Canlet, Julien Arroyo, Agnès Bonnet, Cécile M. D. Bonnefont. Identification of Plasmatic Biomarkers of Foie Gras Qualities in Duck by Metabolomics. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.628264
|
| 30 |
Yuri A. Lawrence, Blake C. Guard, Jörg M. Steiner, Jan S. Suchodolski, Jonathan A. Lidbury, Juan J. Loor. Untargeted metabolomic profiling of urine from healthy dogs and dogs with chronic hepatic disease. PLOS ONE 2019; 14(5): e0217797 doi: 10.1371/journal.pone.0217797
|
| 31 |
Niama Ezzaidi, Xiang Zhang, Olabisi Oluwabukola Coker, Jun Yu. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Letters 2019; 459: 186 doi: 10.1016/j.canlet.2019.114425
|
| 32 |
Qian Feng, Yuanmeng Li, Yuwei Yang, Jiafu Feng. Urine Metabolomics Analysis in Patients With Normoalbuminuric Diabetic Kidney Disease. Frontiers in Physiology 2020; 11 doi: 10.3389/fphys.2020.578799
|
| 33 |
Aihua Zhang, Qiang Yang, Hui Sun, Xijun Wang. Mass Spectrometry‐Based Metabolomics in Clinical and Herbal Medicines. 2021; : 1 doi: 10.1002/9783527835751.ch1
|
| 34 |
Yanjie Zhang, Yajun Sun, Qin Miao, Shilong Guo, Qi Wang, Tianyuan Shi, Xinsheng Guo, Shuai Liu, Guiding Cheng, Chuansheng Wang, Ruiling Zhang. Serum metabolomics analysis in patients with alcohol dependence. Frontiers in Psychiatry 2023; 14 doi: 10.3389/fpsyt.2023.1151200
|
| 35 |
Eugenia Carril, María Pilar Valdecantos, Borja Lanzón, Santiago Angulo, Ángela M. Valverde, Joanna Godzien, Francisco Javier Rupérez. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet. Journal of Pharmaceutical and Biomedical Analysis 2020; 178: 112958 doi: 10.1016/j.jpba.2019.112958
|
| 36 |
Lars Ove Dragsted, Kajetan Trošt. The Human Gut-Liver-Axis in Health and Disease. 2019; : 147 doi: 10.1007/978-3-319-98890-0_10
|
| 37 |
George N. Ioannou, G. A. Nagana Gowda, Danijel Djukovic, Daniel Raftery. Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. Metabolites 2020; 10(4): 168 doi: 10.3390/metabo10040168
|
| 38 |
Jose Rodríguez-Morató, Óscar J Pozo, Josep Marcos. Targeting Human Urinary Metabolome by LC–MS/MS: A Review. Bioanalysis 2018; 10(7): 489 doi: 10.4155/bio-2017-0285
|
| 39 |
Mojgan Masoodi, Amalia Gastaldelli, Tuulia Hyötyläinen, Enara Arretxe, Cristina Alonso, Melania Gaggini, Julia Brosnan, Quentin M. Anstee, Oscar Millet, Pablo Ortiz, Jose M. Mato, Jean-Francois Dufour, Matej Orešič. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology & Hepatology 2021; 18(12): 835 doi: 10.1038/s41575-021-00502-9
|
| 40 |
Xiao-jun Gou, Shanshan Gao, Liang Chen, Qin Feng, Yi-yang Hu. A Metabolomic Study on the Intervention of Traditional Chinese Medicine Qushi Huayu Decoction on Rat Model of Fatty Liver Induced by High-Fat Diet. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/5920485
|
| 41 |
Brianna Cyr, Robert W. Keane, Juan Pablo de Rivero Vaccari. ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. International Journal of Molecular Sciences 2020; 21(22): 8580 doi: 10.3390/ijms21228580
|
| 42 |
Danial Efendy Goon, Sharaniza Ab-Rahim, Amir Hakimi Mohd Sakri, Musalmah Mazlan, Jen Kit Tan, Mardiana Abdul Aziz, Norizal Mohd Noor, Effendi Ibrahim, Siti Hamimah Sheikh Abdul Kadir. Untargeted serum metabolites profiling in high-fat diet mice supplemented with enhanced palm tocotrienol-rich fraction using UHPLC-MS. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-00454-9
|
| 43 |
Heng Yuan, Eun-Soo Jung, Soo-Wan Chae, Su-Jin Jung, James W. Daily, Sunmin Park. Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics. Nutrients 2024; 16(18): 3061 doi: 10.3390/nu16183061
|
| 44 |
David S. Wishart. Metabolomics for Investigating Physiological and Pathophysiological Processes. Physiological Reviews 2019; 99(4): 1819 doi: 10.1152/physrev.00035.2018
|
| 45 |
Diren Beyoğlu, Jeffrey R. Idle. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. Metabolites 2020; 10(2): 50 doi: 10.3390/metabo10020050
|
| 46 |
Ashraf Abbass Basuni, Dina Sweed, Mohammed Fathey Elgazzar, Ashraf Khalil. Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease. Egyptian Liver Journal 2024; 14(1) doi: 10.1186/s43066-024-00378-9
|
| 47 |
Stefano Gitto, Filippo Schepis, Pietro Andreone, Erica Villa. Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives. Metabolites 2018; 8(1): 17 doi: 10.3390/metabo8010017
|
| 48 |
Huikuan Chu, Yi Duan, Ling Yang, Bernd Schnabl. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut 2019; 68(2): 359 doi: 10.1136/gutjnl-2018-316307
|
| 49 |
Nikolaos Perakakis, Konstantinos Stefanakis, Christos S. Mantzoros. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020; 111: 154320 doi: 10.1016/j.metabol.2020.154320
|
| 50 |
Liyan Liu, Jinhui Zhao, Runan Zhang, Xuemei Wang, Yan Wang, Yang Chen, Rennan Feng. Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease. Journal of Pharmaceutical and Biomedical Analysis 2021; 200: 114058 doi: 10.1016/j.jpba.2021.114058
|
| 51 |
Wei-Wei Li, Yan Yang, Qi-Gang Dai, Li-Li Lin, Tong Xie, Li-Li He, Jia-Lei Tao, Jin-Jun Shan, Shou-Chuan Wang. Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome. Metabolomics 2018; 14(7) doi: 10.1007/s11306-018-1387-z
|
| 52 |
Emma J. Robinson, Matthew C. Taddeo, Xin Chu, Weixing Shi, Craig Wood, Christopher Still, Virginia G. Rovnyak, David Rovnyak. Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted 1H-NMR Metabolomics. Metabolites 2021; 11(11): 737 doi: 10.3390/metabo11110737
|
| 53 |
Pankaj Prabhakar, Vijay Marakala, Dhanya Sacheendran, Thomas George, Rhea Katherine D'souza, Princy Louis Palatty, Manjeshwar Shrinath Baliga. Ginger (Zingiber officinale Roscoe; Family: Zingiberaceae) in Non-Alcoholic Fatty Liver Disease: Review on the Existing Scientific Evidence and Way Forward. Current Nutrition & Food Science 2024; 20(7): 789 doi: 10.2174/1573401319666230913122317
|
| 54 |
Ahmad Moolla, Jasper de Boer, David Pavlov, Amin Amin, Angela Taylor, Lorna Gilligan, Beverly Hughes, John Ryan, Eleanor Barnes, Zaki Hassan‐Smith, Jane Grove, Guruprasad P. Aithal, An Verrijken, Sven Francque, Luc Van Gaal, Matthew J. Armstrong, Phillip N. Newsome, Jeremy F. Cobbold, Wiebke Arlt, Michael Biehl, Jeremy W. Tomlinson. Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology & Therapeutics 2020; 51(11): 1188 doi: 10.1111/apt.15710
|